Company: PSTV
Filing Date: 2025-07-21
Form Type: DEF 14A
Source: 0001140361-25-026611
Chunk: 46

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-21
Form: DEF 14A
Chunk 46
---
 providing a continuing financial incentive to maximize long-term value for our stockholders and by encouraging our executive officers to continue in our employment for the long-term. With respect to net income, specifically, because we are not a commercial-stage company, we did not have any revenue during the periods presented, other than revenue associated with grants. Consequently, our company does not consider net loss as a performance measure for our executive compensation program. In 2023, our net loss increased from 2022, which was primarily due to increases in research and development expenses and costs associated with the settlement of litigation. The graphs below compare the compensation actually paid to our Chief Executive Officer and the average of the compensation actually paid to our remaining NEOs, with (i) our cumulative TSR, and (ii) our net income, in each case, for the fiscal years ended December 31, 2022, 2023 and 2024. TSR amounts reported in the graph assume an initial fixed investment of $100.

27

TABLE OF CONTENTS

The following graph illustrates the relationship during 2022, 2023 and 2024 of the CAP for our Chief Executive Officer and other NEOs, calculated pursuant to SEC rules, to our net loss. Equity Compensation Plan Information The following table gives information, as of December 31, 2024, about shares of our Common Stock that may be issued upon the exercise of outstanding options, and shares remaining available for issuance under all of our equity compensation plans:

| Plan Category                                                 |     | Number of securities to be issued 
      upon exercise of outstanding 
                options and rights |     | Weighted-average exercise 
      price of outstanding 
        options and rights |     | Number of securities remaining 
  available for future issuance 
      under equity compensation 
    plans (excluding securities 
        reflected in column(a)) |
|                                                               |     |                                -a |     |                        -b |     |                             -c |
| Equity compensation plans not approved by security holders(1) |     |                            23,897 |     |                    $43.42 |     |                         62,908 |
| Equity compensation plans approved by security holders(2)     |     |                           574,643 |     |                     $5.57 |     |                        692,596 |
| Total                                                         |     |                           598,540 |     |                     $7.08 |     |                        755,504 |

| (1) | Represents (i) options outstanding that were issued under